Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Inclusion Criteria:

• Male and female subjects ages 2 to 17 years with clinical diagnosis of chronicplaque psoriasis and stable disease for at least 3 months prior to the baselinevisit

• Subject with plaque psoriasis covering ≥ 3% of the BSA at screening and baseline

• A PGA score of ≥ 2 at screening and baseline

• Female subjects of childbearing potential who are engaging in sexual activity thatcould lead to pregnancy should use acceptable birth control methods

• Must not be pregnant

• Subject, subject's parent, or legal representative must be capable of giving writteninformed consent/assent

Exclusion Criteria:

• Psoriasis other than plaque variant

• Any sign of infection of any of the psoriatic lesions

• Immunocompromised at screening

• Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0xthe upper limit of normal (ULN)

• Screening total bilirubin > 1.5x ULN

• Current or chronic history of liver disease

• Current or history of cancer within 5 years except for adequately treated cutaneousbasal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix

• Major surgery within 8 weeks prior to baseline or has a major surgery planned duringthe study

• Known history of clinically significant drug or alcohol abuse in the last year priorto baseline

• Use of any prohibited medication or procedure within the indicated period before thebaseline visit until the completion of the study completion or study discontinuation

• History of or ongoing serious illness or medical, physical, or psychiatriccondition(s) that, in the Investigator's opinion may interfere with the subject'sparticipation in the study, interpretation of results, safety of the subject orability to understand and give informed consent

• Pregnant or lactating females.

• History of sensitivity to the study medications, or components thereof or a historyof drug or other allergy that, in the opinion of the Investigator or MedicalMonitor, contraindicates their participation

• Previous known participation in a clinical study with tapinarof (previously known asGSK2894512 and WBI-1001)